Meyka Pro banner
Akso Health Group

Akso Health Group Fundamental Analysis (NASDAQ: AHG)

AHG●NASDAQ
HealthcareMedical - Distribution
$1.26
$0.07(5.26%)
U.S. Market opens in 41h 52m

Akso Health Group Fundamental Analysis (NASDAQ: AHG)

Akso Health Group (NASDAQ: AHG) shows moderate financial fundamentals with a PE ratio of -18.60, profit margin of -2.07%, and ROE of -15.11%. The company generates $0.0B in annual revenue with moderate year-over-year growth of 5.12%.

Key Strengths

PEG Ratio-0.13
Current Ratio21.77

Areas of Concern

ROE-15.11%
Operating Margin-28.92%
Cash Position0.02%
We analyze AHG's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -135.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-135.5/100

We analyze AHG's fundamental strength across five key dimensions:

Efficiency Score

Weak

AHG struggles to generate sufficient returns from assets.

ROA > 10%
-15.11%

Valuation Score

Excellent

AHG trades at attractive valuation levels.

PE < 25
-18.60
PEG Ratio < 2
-0.13

Growth Score

Moderate

AHG shows steady but slowing expansion.

Revenue Growth > 5%
5.12%
EPS Growth > 10%
-6.67%

Financial Health Score

Excellent

AHG maintains a strong and stable balance sheet.

Debt/Equity < 1
0.00
Current Ratio > 1
21.77

Profitability Score

Weak

AHG struggles to sustain strong margins.

ROE > 15%
-1510.67%
Net Margin ≥ 15%
-2.07%
Positive Free Cash Flow
No

Key Financial Metrics

Is AHG Expensive or Cheap?

P/E Ratio

AHG trades at -18.60 times earnings. This suggests potential undervaluation.

-18.60

PEG Ratio

When adjusting for growth, AHG's PEG of -0.13 indicates potential undervaluation.

-0.13

Price to Book

The market values Akso Health Group at 4.99 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

4.99

EV/EBITDA

Enterprise value stands at -655.44 times EBITDA. This is generally considered low.

-655.44

How Well Does AHG Make Money?

Net Profit Margin

For every $100 in sales, Akso Health Group keeps $-2.07 as profit after all expenses.

-2.07%

Operating Margin

Core operations generate -28.92 in profit for every $100 in revenue, before interest and taxes.

-28.92%

ROE

Management delivers $-15.11 in profit for every $100 of shareholder equity.

-15.11%

ROA

Akso Health Group generates $-15.11 in profit for every $100 in assets, demonstrating efficient asset deployment.

-15.11%

Following the Money - Real Cash Generation

Operating Cash Flow

Akso Health Group generates limited operating cash flow of $-21.95M, signaling weaker underlying cash strength.

$-21.95M

Free Cash Flow

Akso Health Group generates weak or negative free cash flow of $-125.74M, restricting financial flexibility.

$-125.74M

FCF Per Share

Each share generates $-0.15 in free cash annually.

$-0.15

FCF Yield

AHG converts -9.97% of its market value into free cash.

-9.97%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-18.60

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.13

vs 25 benchmark

P/B Ratio

Price to book value ratio

4.99

vs 25 benchmark

P/S Ratio

Price to sales ratio

77.18

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.002

vs 25 benchmark

Current Ratio

Current assets to current liabilities

21.77

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.15

vs 25 benchmark

ROA

Return on assets percentage

-0.15

vs 25 benchmark

ROCE

Return on capital employed

-0.02

vs 25 benchmark

How AHG Stacks Against Its Sector Peers

MetricAHG ValueSector AveragePerformance
P/E Ratio-18.6031.03 Better (Cheaper)
ROE-15.11%509.00% Weak
Net Margin-207.10%5168.00% Weak
Debt/Equity0.000.05 Strong (Low Leverage)
Current Ratio21.775.60 Strong Liquidity
ROA-15.11%-176.00% (disorted) Weak

AHG outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Akso Health Group's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-95.94%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

96.40%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

100.04%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ